- Report
- August 2026
- 190 Pages
Global
From €4386EUR$4,750USD£3,712GBP
- Report
- July 2026
- 114 Pages
Global
From €4386EUR$4,750USD£3,712GBP
- Report
- July 2026
- 130 Pages
Global
From €4386EUR$4,750USD£3,712GBP
- Report
- August 2026
- 110 Pages
Global
From €4386EUR$4,750USD£3,712GBP
- Report
- August 2026
- 111 Pages
Global
From €4386EUR$4,750USD£3,712GBP
- Report
- August 2026
- 119 Pages
Global
From €4386EUR$4,750USD£3,712GBP
- Report
- July 2026
- 200 Pages
Global
From €4386EUR$4,750USD£3,712GBP
- Report
- July 2026
- 120 Pages
Global
From €4386EUR$4,750USD£3,712GBP
- Report
- July 2026
- 112 Pages
Global
From €4386EUR$4,750USD£3,712GBP
- Report
- July 2026
- 120 Pages
Global
From €4386EUR$4,750USD£3,712GBP
- Report
- July 2026
- 118 Pages
Global
From €4386EUR$4,750USD£3,712GBP
- Report
- July 2026
- 130 Pages
Global
From €4386EUR$4,750USD£3,712GBP
- Report
- June 2026
- 132 Pages
Global
From €4386EUR$4,750USD£3,712GBP
- Report
- May 2026
- 152 Pages
Global
From €3647EUR$3,950USD£3,087GBP
- Report
- May 2026
- 151 Pages
Global
From €3647EUR$3,950USD£3,087GBP
- Report
- May 2026
- 148 Pages
Global
From €3647EUR$3,950USD£3,087GBP
- Report
- November 2025
- 150 Pages
Global
From €4478EUR$4,850USD£3,790GBP
- Report
- August 2026
- 160 Pages
Global
From €3065EUR$3,320USD£2,595GBP
€3832EUR$4,150USD£3,243GBP
- Report
- August 2026
- 160 Pages
Global
From €3065EUR$3,320USD£2,595GBP
€3832EUR$4,150USD£3,243GBP
- Report
- August 2026
- 160 Pages
Global
From €3065EUR$3,320USD£2,595GBP
€3832EUR$4,150USD£3,243GBP

BeiGene is a market within the context of Oncology Drugs, which are drugs used to treat cancer. These drugs are used to target and destroy cancer cells, while minimizing damage to healthy cells. BeiGene is a biopharmaceutical company that develops and commercializes innovative molecularly targeted and immuno-oncology drugs for the treatment of cancer. The company focuses on developing therapies that target cancer cells with precision and accuracy, while also providing a safe and effective treatment for patients. BeiGene's portfolio includes a range of drugs, including small molecules, antibodies, and other biologics. The company also has a pipeline of novel therapies in development.
BeiGene is one of many companies in the Oncology Drugs market. Other companies include AstraZeneca, Bristol-Myers Squibb, Eli Lilly, Merck, Novartis, Pfizer, and Roche. Show Less Read more